This article is more than 5 years old. Information may no longer be current.
VIDEO: IBS-C shows ‘substantial burden,’ available treatments insufficient
Click Here to Manage Email Alerts
ORLANDO — In this exclusive video from the World Congress of Gastroenterology at ACG 2017, Eamonn M.M. Quigley, MD, MACG, professor of medicine at Weill Cornell Medical College, and chief of gastroenterology and hepatology at Houston Methodist Hospital, discusses survey results from the BURDEN IBS-C Study, which showed constipation-predominant irritable bowel syndrome has a significant burden on patients, and that patients and health care providers alike find available treatments unsatisfactory.
“We’ve shown yet again that IBS-C has a significant impact on quality of life. However, we have shown that the perception of the patient and the perception of the health care provider with regard to that impact seems to be quite different, and I think this deserves further investigation,” Quigley told Healio Gastroenterology and Liver Disease. Further, “we have shown that IBS-C is not an infrequent reason for people to go to the emergency room, and we’ve also seen that there’s still a significant unmet need in terms of treatment.”
Highlights from the study data, according to a press release from Synergy Pharmaceuticals, include:
- 60% of more than 1,300 patients surveyed said their symptoms were “somewhat to extremely bothersome”;
- 43% reported being “frustrated” by their symptoms, and 28% said their condition was “stressful”;
- respondents said their condition affected work or school productivity 4 days per month on average, causing them to miss 1.5 work or school days per month;
- most health care providers recognized their patients’ frustration and stress, but underestimated how often patients were accepting of their condition; and
- 78% of patients and 79% of health care providers were unsatisfied with current treatments.
Reference:
Quigley EMM, et al. Abstract P2019. Presented at: World Congress of Gastroenterology at American College of Gastroenterology Annual Scientific Meeting; Oct. 13-18, 2017; Orlando, FL.
Disclosures: Quigley reports consulting for Synergy Pharmaceuticals, who funded the study.